FAQ

recombinant antihemophilic factor VIII

Known as: recombinant factor viii, rfviii 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1987-2017
051019872017

Related topics

Related topics

7 relations

Narrower (6)

AlphanateAntihemophilic Factor, Human RecombinantKogenateOctocog alfa
(More)

Broader (1)

Factor VIII

Related mentions per year

Related mentions per year

1947-2018
19401960198020002020
recombinant antihemophilic factor VIII
Antihemophilic Factor, Human Recombinant
Factor VIII
Kogenate
Recombinate
Wilate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq® ) in children with severe haemophilia A: efficacy, safety and pharmacokinetics.
INTRODUCTION Nuwiq® (Human-cl rhFVIII) is a new-generation recombinant factor VIII (rFVIII) protein, without chemical… (More)
Is this relevant?
2015
2015
Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials
Recombinant factor VIII (rFVIII) products provide a safe and efficacious replacement therapy for prevention and treatment of… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2014
2014
Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011.
The effect of recombinant factor VIII (rFVIII) brand on inhibitor development was investigated in all 407 severe hemophilia A… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 4
Is this relevant?
2013
2013
Results from a large multinational clinical trial (guardianâ„¢1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.
Recombinant factor VIII (rFVIII) products provide a safe and efficacious replacement therapy for prophylaxis and treatment of… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2013
2013
Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.
INTRODUCTION The preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII, was… (More)
Is this relevant?
2013
2013
Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and…
Recombinant factor VIII (rFVIII) products provide a safe and efficacious replacement therapy for prophylaxis and treatment of… (More)
Is this relevant?
2013
2013
Prolonged effect of a new O-glycoPEGylated FVIII (N8-GP) in a murine saphenous vein bleeding model.
Prophylaxis in severe haemophilia significantly increases health-related quality of life for patients, but the dosing frequency… (More)
Is this relevant?
2012
2012
Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice.
N8 is a new recombinant factor VIII (rFVIII) compound produced and formulated without human- or animal-derived protein. The aims… (More)
  • figure 1
  • table 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
2007
2007
Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria.
An open-label, multicentre, postmarketing surveillance study conducted in Germany and Austria with recombinant factor VIII… (More)
Is this relevant?
1987
1987
Characterization of recombinant human factor VIII.
Recently, complete human factor VIII DNA clones have been obtained and subsequently expressed in baby hamster kidney cells (Wood… (More)
  • figure 1
  • figure 3
  • figure 4
  • figure 8
  • figure 6
Is this relevant?